拉米夫定联合柴胡总皂苷抗乙型肝炎病毒的实验研究

目的研究拉米夫定联合柴胡总皂苷在体内抗乙型肝炎病毒（HBV）的作用。方法采用乙型肝炎动物模型，用拉米夫定联合柴胡总皂苷（联合组）口服治疗28d，停药观察7d，并与单用拉米夫定（拉米组）、柴胡总皂苷（柴胡组）作为对照，检测用药前后血清中HBVDNA、HBsAg及血清转氨酶（ALT、AST）。结果联合组用药后能显著降低血清中HBVDNA及HBsAg水平（P〈0．05），停药7d后HBVDNA及HBsAg含量较用药28d时无明显“反跳”（P〉0．05），拉米组与柴胡组停药7d后有明显回升（P〈0．05）。各组用药28d及停药7d后AIJT及AST含量同一时相内未有明显变化（P〉0．05）。结论拉米夫定联合柴胡总皂苷用药后在体内有抗乙型肝炎病毒的作用，抗病毒效果稳定持久。

Experimental study on Lamivudine combined with Saikosaponins in anti-hepatitis B virus

Objective To study the effect of anti-hepatitis B virus of Lamivudine combined with Saikosaponins in vivo. Methods Chongqing duck hepatitis B model was selected and given to Lamivudine combined with Saikosaponins(combined group) oral treatment 28d, then the ducks were observed 7d after drug withdrawal. The levels of serum HBV DNA, HBsAg and transaminase(ALT, AST) were detected before and after treatment, and compared with that in Lamivudine group and Saikosaponins group as control. Results In combined group,the levels of serum HBV DNA and HbsAg were significantly decreased(P ＜ 0.05), and 7d after drug withdrawal the levels of serum HBV DNA and HBsAg showed no" anti-jump" compared with that at drug treatment 28d(P ＞ 0.05). In Lamivudine group and Saikosaponins group the levels of those increased again 7d after drug withdrawal (P ＜ 0. 05). In each group the levels of serum ALT and AST did not change within the same phase during drug treatment 28d and 7d after drug withdrawal(P ＞ 0. 05). Conclusion Lamivudine combined with Saikosaponins in vivo had the effect of anti-hepatitis Bvirus, and the effect was stable and lasting.